Response to “Survival advantage for Etoposide/Cisplatin over Paclitaxel/Carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: A subgroup analysis for ECOG 2 patients would be of great interest”

performance statuslocally-advanced NSCLCinoperableconcomitantChemoradiotherapy

http://ift.tt/2htha7Z